Tobacco and Smoking Cessation

Nan-Ying Chiu ； Cheng-Ju Chang

《台灣精神醫學》 33卷3期 (2019/09) Pp. 125-134

https://doi.org/10.4103/TPSY.TPSY_26_19

摘要

Background: Tobacco products have been used by human for a long history. The prevalence of tobacco use varies in different countries. Tobacco use is different from tobacco use disorder. Tobacco use disorder is a problematic pattern of tobacco use leading to significant distress or impairment. Cigarette smoking is a chronic relapsing substance use disorder caused by addiction to nicotine. Tobacco smoke contains over 7,000 different chemical compounds, of which 93 of them are harmful substances. Methods: In this review, the authors intended to address the issues of harmful effects of cigarette smoking and how to cease smoking. Results: Abundant studies showed that tobacco use is the main risk factor of morbidity and mortality in the world. People who use tobacco products should be advised to quit smoking and offered appropriate treatment. It is better for health-care providers to make the smoking cessation treatment as a standard component of medical care. Data from evidence-based literature showed that smoking cessation therapy can significantly raise smoking cessation rates and should be routinely in persons who are willing to quit tobacco smoking. Smoking cessation treatment includes psychosocial interventions and pharmacological treatment, which may be used in combination. Nonpharmacological management may be individual or group sessions, and it may include motivational interviewing, cognitive behavioral therapy, and others. Delivery formats of stop-smoking interventions are varied. Pharmacological therapy includes nicotine replacement treatment and smoking aids such as bupropion and varenicline. Morbidity and mortality rates are decreased with tobacco cessation at any point in time, although cessation before the age of 40 years has the most significant effect. Conclusion: The Tobacco Hazards Prevention Act took effect since 1997 in Taiwan. Rates of Taiwanese tobacco use have been steadily declining. Brilliant achievements in the field of tobacco control in Taiwan draw international attention.

關鍵字

comorbidity and mortality of cigarette smoking ； nicotine replacement ； substance use disorder ； varenicline

參考文獻

GBD 2015 Tobacco Collaborators: Smoking prevalence and attributabledisease burden in 195 countries and territories, 1990-2015: a systematic analysis from the global burden of disease study 2015. Lancet 2017; 389: 1885-906.

Higa-McMillan CK, Smith RL, Chorpita BF, et al.: Common and unique factors associated with DSM-IV-TR internalizing disorders in children. J Abnorm Child Psychol 2008; 36: 1279-88.

Kalkhoran S, Benowitz NL, Rigotti NA: Prevention and treatment of tobacco use: JACC health promotion series. J Am Coll Cardiol 2018; 72: 1030-45.

McNally WD: The tar in cigarette smoke and its possible effects. Am J Cancer 1932; 16: 1502-14.

World Health Organization, Research for International Tobacco Control: WHO Report on the Global Tobacco Epidemic. Geneva, Switzerland: World Health Organization, 2018.